Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals (MDGL) Financial Statements


Madrigal Pharmaceuticals Financial Overview

Madrigal Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-19.935; its P/E ratio is -11.15; Madrigal Pharmaceuticals is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-6.23. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue----$ 0.00
Gross Profit-----
EBIT$ -95.24M$ -82.90M$ -98.71M$ -85.30M$ -79.69M
EBITDA$ -94.43M$ -82.22M$ -98.15M$ -84.86M$ -79.57M
Net Income Common Stockholders$ -98.74M$ -85.80M$ -76.90M$ -85.91M$ -81.20M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 232.35M$ 298.42M$ 329.48M$ 358.77M$ 153.19M
Total Assets$ 237.96M$ 302.46M$ 331.94M$ 362.57M$ 158.64M
Total Debt$ 116.56M$ 99.66M$ 84.62M$ 49.89M$ 49.81M
Net Debt$ -115.79M$ -198.76M$ -244.86M$ -308.88M$ -103.38M
Total Liabilities$ 215.72M$ 198.96M$ 182.31M$ 165.18M$ 147.97M
Stockholders Equity$ 22.25M$ 103.86M$ 149.69M$ 197.39M$ 10.67M
Cash Flow-
Free Cash Flow$ -85.26M$ -75.38M$ -84.10M$ -58.54M$ -59.10M
Operating Cash Flow$ -84.92M$ -75.31M$ -84.07M$ -58.52M$ -59.07M
Investing Cash Flow$ 50.20M$ -3.73M$ -186.86M$ 66.39M$ 65.14M
Financing Cash Flow$ 19.58M$ 42.93M$ 52.69M$ 264.34M$ 0.00
Currency in USD

Madrigal Pharmaceuticals Earnings and Revenue History

Madrigal Pharmaceuticals Debt to Assets

Madrigal Pharmaceuticals Cash Flow

Madrigal Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis